Advertisement
The report also finds that nearly three-quarters of physicians say theyhave switched patients to Merck's Januvia as a result of the Avandiameta-analysis. More than 80 percent of surveyed physicians say they willincrease the number of total prescriptions they write for Januvia over thenext two years. Although clinicians and managed care organizations surveyedconsider metformin (Bristol-Myers Squibb's Glucophage, generics) to offer thebest overall safety and efficacy, Januvia received the second greatest numberof votes for "agent with the best overall safety profile" and for "lowest riskof hypoglycemia." In comparison, Amylin/Eli Lilly's Byetta was chosen byendocrinologists and MCOs as the agent least likely to cause weight gain, andthe drug also received the third greatest number of votes for "agent with thebest overall efficacy profile."
Advertisement
"Cardiovascular safety concerns have significantly impacted prescriptionsfor Avandia and created opportunities for other antidiabetic agents," saidDonny Wong, Ph.D., principal analyst at Decision Resources. "Nearlythree-quarters of physicians say they have switched patients to Januvia as aresult of the Avandia meta-analysis, and one-third of PCPs andendocrinologists say they have switched patients to Byetta followingpublication of the Avandia meta-analysis. Nevertheless, Takeda's Actos willcontinue to be the market share leader among oral antidiabetic agents untilthe drug loses patent protection in 2011."
Avandia One Year Later-A Physician and Payer Perspective is based on aU.S. survey of 74 PCPs, 70 endocrinologists and 20 managed care pharmacydirectors. Their responses were compared to assess similarities anddifferences of opinion regarding clinical, economic, and scientific factors.
About Physician & Payer Forum
Physician & Payer Forum is a primary research service from DecisionResources that offers access to high volume-prescribing physicians,specialists, and managed care organization representatives in the UnitedStates; analysis of events and survey participants' responses to them; insightinto prescribing patterns; and an examination of the implications of eventsand issues for the pharmaceutical market.
About Decision Resources
Decision Resources (http://www.DecisionResources.com) is a world leader inmarket research publications, advisory services, and consulting designed tohelp clients shape strategy, allocate resources, and master their chosenmarkets. Decision Resources is a Decision Resources, Inc. company.All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders. For more information, contact: Elizabeth Marshall Decision Resources 781-296-2563 [email protected]
SOURCE Decis
